Skip to content

Dietary Intervention With Únicla Dairy Products (DANTIAN)

Dietary Intervention With Únicla Dairy Products, Naturally Enriched With Selenium and Omega-3 Fatty Acids, May Improve Thyroid-stimulating Hormone (TSH) Levels in Women With Subclinical Hypothyroidism

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05019118
Acronym
DANTIAN
Enrollment
90
Registered
2021-08-24
Start date
2021-09-06
Completion date
2022-05-30
Last updated
2021-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinical Hypothyroidism

Keywords

Hypothyroidism, selenium, women

Brief summary

Dietary intervention with Únicla dairy products, naturally enriched with selenium and omega-3 fatty acids, may improve thyroid-stimulating hormone (TSH) levels in women with subclinical hypothyroidism

Detailed description

To analyze in women diagnosed with subclinical hypothyroidism, the effects of consumption of dairy products rich in selenium and omega-3 on symptoms related to thyroid disease and blood lipid profile, inflammatory response, and fatty acid levels in the red blood cell membrane among others.

Interventions

UNICLA milk naturally enriched in selenium and omega-3.

OTHERExperimental yogur

UNICLA yogur naturally enriched in selenium and omega-3.

OTHERExperimental fresh cheese

UNICLA fresh cheese naturally enriched in selenium and omega-3.

Conventional milk

OTHERPlacebo yogur

Conventional yogur

OTHERPlacebo fresh cheese

Conventional fresh cheese

Sponsors

Galician South Health Research Institute
CollaboratorNETWORK
Cooperativas Lacteas Unidas
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

The masking process will be triple blind, that is, both the participating women, the research staff (including those in charge of delivering the products and the one who performs and interprets the measurements), as well as the analyst, won't know at any time what group belong to patients. All the products in the study (Únicla dairy) as well as their respective placebos (conventional FEIRACO equivalent products) will maintain a similar format and labeling, with the organoleptic characteristics of dairy products being very similar. Masking will be opened at the time that the last data interpretation of the last subject included was made and before starting the statistical analysis

Intervention model description

Randomized, masked and controlled nutritional intervention study

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of subclinical hypothyroidism * TSH levels between 3 and 10 mIU / L * Normal levels of free triiodothyronine ( T3) and free thyroxine (T4) * Without previous or current treatment with levothyroxine

Exclusion criteria

* Thyroid surgery or reception of radioactive iodine in a previous period of 12 months * History of cardiovascular disease and / or thrombosis * Established diagnosis or clinical suspicion of kidney or liver failure, chronic infections, blood diseases, type I diabetes and type II diabetes * Drug treatments that affect thyroid function (corticosteroids, amiodarone, propranolol, lithium) * Statin treatment and / or hormone replacement therapy * Adjuvant treatment with trace elements, vitamins or antidepressant and antipsychotic drugs * Hospitalization for serious illness or elective surgery in the past 4 weeks * Diseases and / or treatments that affect intestinal absorption (proton pump inhibitors) * Pregnant, planning to become pregnant or breastfeeding women * Consumption of ω-3 PUFA type food supplements * Intolerance and / or allergy to lactose and / or cow's milk proteins * Any pathology that requires close control, advises against their participation or there is an inability to move independently * Habitual residence outside the study's influence area * Participation in another clinical trial with drugs, or in other experimental studies * Refuse to sign the informed consent

Design outcomes

Primary

MeasureTime frameDescription
Percentage of patients with changes in thyroid function3 monthsthyroid stimulating hormone blood level

Secondary

MeasureTime frameDescription
HDL level3 monthshigh density lipoproteins blood level
selenium3 monthsselenium blood level
IL-63 monthsInterleukina-6 blood level
Fecal calprotectin3 monthsFecal calprotectin feces level

Countries

Spain

Contacts

Primary ContactMaría Reyes Pérez-Fernández, PhD
Maria.Reyes.Perez.Fernandez@sergas.es676520946
Backup ContactIsmael Martínez-Lede, graduate
ismael.martinez@clun.es0034609563353

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026